All Articles

A $300,000 financing will fuel Lomiko's push to develop battery-grade graphite in Quebec and explore a strategic antimony-gold prospect in Newfoundland.

MENA's streaming leader Anghami doubles its subscribers after its OSN+ merger, but a $37M loss raises questions about its high-stakes growth strategy.

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

As Equity Bancshares preps its Q4 report, investors eye its M&A success, margin health, and 2026 guidance amid a complex economic landscape.

Italian luxury knitwear maker Zanieri completes a reverse merger with Everlert, Inc., gaining a US public listing to fund global expansion and brand growth.

After a year of major acquisitions and AI-driven innovation, all eyes are on Labcorp's strategic vision for 2026 at the J.P. Morgan Healthcare Conference.

A critical railway is down, halting iron ore shipments. Champion Iron projects calm, but the incident highlights logistical risks in a bullish market.

Treace Medical heads to the J.P. Morgan conference to showcase its surgical tech, facing tough questions on growth amid competition and market shifts.

INVO Fertility realigns its top brass, positioning a deal-making veteran to lead an aggressive clinic acquisition strategy in a booming market.

As 10x Genomics preps for its J.P. Morgan spotlight, investors seek a clear path to profit amid fierce competition and groundbreaking innovation.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

Sidus Space nets nearly $15M in a new offering to scale satellite production and defense tech, sparking investor optimism despite financial pressures.

Investors await Polaris's Q4 results on Jan. 27, seeking clarity on market share gains, tariff impacts, and the future of its Indian Motorcycle brand.

The investment firm renews its plan to repurchase up to 5% of its units, signaling a strong belief that its market price is below its intrinsic value.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Amidst legal industry fears of generative AI, BriefCatch's $6M funding and stellar retention prove the value of a trusted, specialized AI writing partner.

Emmaus Life Sciences outsources its sickle cell drug Endari® in North America to focus on global growth, as NeoImmuneTech gains a key U.S. market foothold.

KORU Medical seeks FDA clearance for its FreedomEDGE® system with a key breast cancer drug, signaling a major shift in cancer care delivery.

Amid market volatility and a green energy push, Devon's CEO will outline the firm's strategy for navigating a complex 2026 at a top industry event.

Fitch Ratings awards NETSTREIT a BBB- rating, a milestone affirming its conservative strategy and unlocking new avenues for growth and capital efficiency.